Open AccessLONG-COVID COGNITIVE IMPAIRMENT: COGNITIVE ASSESSMENT AND APOLIPOPROTEIN E (APOE) GENOTYPING CORRELATION IN A BRAZILIAN COHORT
Author(s) -
José Wagner Leonel Tavares-Júnior,
Pedro BragaNeto,
Manoel Sobreira Neto,
Danilo Bretas de Oliveira,
Carmem Gomes,
Safira Gaspar,
Emmanuelle Silva Tavares Sobreira,
Werbety Lucas Queiroz Feitosa,
Leticia Chaves Cunha,
Raquel Carvalho Montenegro
Publication year - 2021
Publication title -
dementia and neuropsychologia
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 0.54
H-Index - 21
ISSN - 1980-5764
DOI - 10.5327/1980-5764.rpda030
Subject(s) - dementia , outpatient clinic , medicine , cognition , neuropsychology , cognitive decline , apolipoprotein e , montreal cognitive assessment , cohort , psychiatry , disease
Background: COVID-19 neurological manifestations were demonstrated during the pandemic, including cognitive impairment. Objectives: To determine the prevalence of cognitive and behavioral complaints (such as dementia, MCI or SCD) in a outpatient sample with recent SARS-COV2 infection. Specific: Evaluate the association of cognitive impairment with the presence of the polymorphism found in the APOE gene and with respiratory disease. Methodology: Observational, longitudinal, prospective clinical study. Inclusion criteria: patients with confirmed Covid-19. Patients are evaluated in an outpatient clinic. They are evaluated through a standardized attendance record, with somatic and cognitive neurological assessment. Cognitive assessment involves the application of cognitive (ACER, MMSE and CDR), functional (Pfeffer) and psychiatric (GDS or Beck) screening instruments, in addition to subsequent extensive neuropsychological assessment. In addition, APOE polymorphism is analysed. Preliminary. Results: To date, 191 patients and 11 controls were evaluated. The average age is 46.5 years, with 65.4% female, 79.16% with 8 or more years of schooling, in addition to 57.5% of the sample with cognitive complaints. Conclusions: The results so far in our study demonstrate that cognitive complaints are frequent in patients even in the chronic phase of the disease.